Revocation of Suspension in Trading of Equity Shares of Vivimed Labs LimitedWe are delighted to inform both exchanges, our valued shareholders, and market participants that BSE Limited and the National Stock Exchange of India Limited (NSE) have officially communicated their decision to revoke the suspension in trading of equity shares of Vivimed Labs Limited. As per the notifications received:Date of Circular/Notice: December 10, 2025Effective Date of Revocation: Trading in equity shares will resume from December 18, 2025.This revocation marks a significant turning point, reinstating liquidity and enabling price discovery for our shareholders. The Company has diligently complied with all requisite regulatory norms, specifically addressing previous non-compliances under SEBI (LODR) Regulations, 2015. We assure you that we will continue in the same spirit for the years to come.We extend our sincere gratitude to both exchanges and our shareholders for their unwavering support and patience throughout this challenging period.We look forward to commencing trading with renewed vigor and commitment to transparency, growth, and sustained shareholder value.The official circulars detailing this revocation are available on the websites of BSE and NSE for further reference.(attached)
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BSE and NSE have officially revoked the trading suspension on Vivimed Labs Limited's equity shares. Trading will resume from December 18, 2025, as per circulars dated December 10, 2025. The company states it has complied with all regulatory requirements, specifically addressing prior non-compliances under SEBI (LODR) Regulations, 2015. This move reinstates liquidity and price discovery for shareholders after the period of suspension.
Resumption of trading brings back liquidity and normal price discovery for existing shareholders, which had been frozen during the suspension period. The event removes a significant overhang but reflects a history of regulatory non-compliance that investors should weigh when assessing risk.